Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dtxsid10151274
Molecular Weight | 5832 g/mol |
---|---|
Molecular Formula | C256H387N65O79S6 |
Hydrogen Bond Donor Count | 86 |
Hydrogen Bond Acceptor Count | 91 |
Rotatable Bond Count | 188 |
Exact Mass | 5829.6654893 g/mol |
Monoisotopic Mass | 5827.6587796 g/mol |
Topological Polar Surface Area | 2350 Ų |
Heavy Atom Count | 406 |
Formal Charge | 0 |
Complexity | 13000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 52 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
2 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32700
Submission : 2018-05-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27184
Submission : 2013-05-15
Status : Active
Type : IV
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39605
Submission : 2024-03-14
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
10 Sep 2022
Reply
06 Sep 2019
Reply
05 Dec 2018
Reply
29 Sep 2021
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A NOVOLOG manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NOVOLOG, including repackagers and relabelers. The FDA regulates NOVOLOG manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NOVOLOG API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A NOVOLOG supplier is an individual or a company that provides NOVOLOG active pharmaceutical ingredient (API) or NOVOLOG finished formulations upon request. The NOVOLOG suppliers may include NOVOLOG API manufacturers, exporters, distributors and traders.
click here to find a list of NOVOLOG suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A NOVOLOG DMF (Drug Master File) is a document detailing the whole manufacturing process of NOVOLOG active pharmaceutical ingredient (API) in detail. Different forms of NOVOLOG DMFs exist exist since differing nations have different regulations, such as NOVOLOG USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NOVOLOG DMF submitted to regulatory agencies in the US is known as a USDMF. NOVOLOG USDMF includes data on NOVOLOG's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NOVOLOG USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NOVOLOG suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NOVOLOG as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NOVOLOG API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NOVOLOG as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NOVOLOG and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NOVOLOG NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NOVOLOG suppliers with NDC on PharmaCompass.
NOVOLOG Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NOVOLOG GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NOVOLOG GMP manufacturer or NOVOLOG GMP API supplier for your needs.
A NOVOLOG CoA (Certificate of Analysis) is a formal document that attests to NOVOLOG's compliance with NOVOLOG specifications and serves as a tool for batch-level quality control.
NOVOLOG CoA mostly includes findings from lab analyses of a specific batch. For each NOVOLOG CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NOVOLOG may be tested according to a variety of international standards, such as European Pharmacopoeia (NOVOLOG EP), NOVOLOG JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NOVOLOG USP).
LOOKING FOR A SUPPLIER?